BWVI Blue Water Ventures International

Blue Water Ventures International 2020 Season is in Motion

Blue Water Ventures International 2020 Season is in Motion

Jacksonville, FL, July 28, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Blue Water Ventures International, Inc. (OTC:BWVI): Greetings from our BWVI team.  It has been a difficult environment in 2020, with COVID-19 affecting most everyone and every business in one way or the other.  Blue Water Ventures International, Inc. and project partner Swordfish Partners, LLC are pleased to report the start of the 2020 dive and recovery season.  The recovery vessel Blue Water Rose is now on her way to Virginia Beach, where the crew will dive to recover samples from a 1911 wreck site.  BWVI anticipates a ten-day window to complete the survey and recovery of samples.

BWVI will then move back to the “SB Pulaski” site off Wrightsville Beach, North Carolina.  Keith Webb, President of Blue Water Ventures, commented, “Our Captain and crew have worked hard in the off season to upgrade our deep dive re-breather system that will enable us to spend longer periods of time while diving so deep.  This deep-water dive opportunity opens the door to an abundance of wrecks with untouched cargos and riches.”

Our team is ready to bring more history back to the surface and share in the journey of the SB Pulaski and its final days at sea back in 1838.  A story that can be told not only through what has been written but what has been and will be found from the Pulaski site as we continue our mission to recover more of its story.  We have had successful seasons finding many historic and valuable pieces with some of the earliest rare, US minted gold shipwreck coins recovered to date which were successfully sold to collectors.  We are excited to get back to what we do best, while keeping the public and shareholders abreast of our recovery efforts with enhanced corporate communications.  We believe we have only just scratched the surface on the SB Pulaski and its cargo with much left to be discovered.  The team is thrilled to be back at it and look forward to reporting back in the near future.

We also plan to relaunch our new website very soon as well as have our financials released which will bring Blue Water back current with OTC markets.  Also of note, the shares outstanding as of today are 68,797,013 and we are happy to report that after 8 years of being public we have remained committed to keeping our share structure intact with non-toxic funding and plan on this being the case moving forward.  Blue Water looks forward to updating shareholders as we get into motion and are pulling up artifacts, valuables, and learning more of the SB Pulaski history.  Follow up on Facebook for updates as we are on the water.

For more timely updates, and info regarding the most up-to-date recoveries be sure to follow our Facebook page at the link below.

About Blue Water Ventures International, Inc.:

The Company is engaged in the business of conducting archaeologically sensitive recoveries of cargo and artifacts from shipwrecks. Its operations to date have focused on shallow water search and recovery projects in less than 150 feet of water. The Company is now expanding its focus to include deep-water salvage of historic and modern-day shipwrecks.

Keith Webb

904-215-7601

EN
28/07/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Blue Water Ventures International

 PRESS RELEASE

Psycheceutical Hosts MAPS Founder and Psychedelic Industry Leader Rick...

Psycheceutical Hosts MAPS Founder and Psychedelic Industry Leader Rick Doblin at Its Drug Development Lab Doblin commented on the potential of the company’s NeuroDirect™ ketamine topical cream to help those suffering from PTSD Psycheceutical Chief Visionary Officer Zappy Zapolin and CEO Chad Harman with MAPS Founder Rick Doblin MIAMI, March 29, 2023 (GLOBE NEWSWIRE) -- ("Psycheceutical" or the "Company") (OTC: BWVI), a bioscience company dedicated to developing cutting-edge technologies for the next generation of mental health treatments, hosted Rick Doblin, the Founder and Preside...

 PRESS RELEASE

Psycheceutical Bioscience, Inc. Announces Observational Research Resul...

Psycheceutical Bioscience, Inc. Announces Observational Research Results for NeuroDirect™ Ketamine Topical Cream in Treating PTSD A pre-clinical observational study published in Drug Development & Delivery found that more than 80% of patients experienced relief within minutes of applying NeuroDirect™ ketamine topical creamPatients indicated their thought processes were clearer and more focused, and were more keenly aware of surroundings MIAMI, March 21, 2023 (GLOBE NEWSWIRE) -- ("Psycheceutical" or the "Company") (OTC: BWVI), a bioscience company dedicated to developing cutting-edge tec...

 PRESS RELEASE

Psycheceutical to Conduct the First Ever Phase I and II Clinical Trial...

Psycheceutical to Conduct the First Ever Phase I and II Clinical Trials of a Novel Ketamine Topical Cream to Treat PTSD Psycheceutical ​​enters into agreement with iNGENū to conduct ​human ​clinical trials of NeuroDirect™ ketamine topical ​in AustraliaPhase I trial will study 20 people to test the safety, tolerability, and pharmacokinetics of a single dose of NeuroDirect™ ketaminePhase II trial will study 115 participants with PTSD and look at the effectiveness of NeuroDirect™ ketamine on improving their symptoms MIAMI, Feb. 15, 2023 (GLOBE NEWSWIRE) -- (OTCPK: BWVI) ("Psycheceutical"...

 PRESS RELEASE

Psycheceutical Announces Completion of Pre-IND Meeting with FDA for To...

Psycheceutical Announces Completion of Pre-IND Meeting with FDA for Topical Ketamine Drug to Treat PTSD Company intends to pursue 505(b)(2) regulatory pathway for novel topical formulation of ketamine for the treatment of PTSD MIAMI, Feb. 02, 2023 (GLOBE NEWSWIRE) -- (OTCPK: BWVI) ("Psycheceutical" or the "Company"), a bioscience company dedicated to developing cutting-edge brain delivery technologies for the next generation of mental health treatments, is pleased to announce it has completed its pre-Investigational New Drug ("IND") meeting with the U.S. Food and Drug Administration (F...

 PRESS RELEASE

Psycheceutical Bioscience Provisional Patent Application for Novel Ket...

Psycheceutical Bioscience Provisional Patent Application for Novel Ketamine Topical for the Treatment of PTSD Topical ketamine formulations could improve the methods of treating post-traumatic stress disorder (PTSD) MIAMI, Jan. 26, 2023 (GLOBE NEWSWIRE) -- ("Psycheceutical" or the "Company") (OTC: BWVI), a bioscience company dedicated to developing cutting-edge treatments for mental health, has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) for the first ketamine topical intended for treating post-traumatic stress disorder (PTSD). The...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch